These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23390943)

  • 1. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum.
    Bern EM; Bousvaros A
    Expert Rev Clin Immunol; 2013 Feb; 9(2):117-27. PubMed ID: 23390943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risks and benefits of early immunosuppression and biological therapy.
    Sands BE
    Dig Dis; 2012; 30 Suppl 3():100-6. PubMed ID: 23295699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
    Kwon JH; Farrell RJ
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inflammatory bowel diseases and lymphoma].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Feb; 82(2):185-9. PubMed ID: 15185593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and progress in pediatric inflammatory bowel disease.
    Rufo PA; Bousvaros A
    Curr Opin Gastroenterol; 2007 Jul; 23(4):406-12. PubMed ID: 17545777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
    Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R; Denis MA; Dewit O
    J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
    Shah SB; Hanauer SB
    Rev Gastroenterol Disord; 2008; 8(3):159-68. PubMed ID: 18957923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic problems and advances in inflammatory bowel disease.
    Odze R
    Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Idiopathic inflammatory bowel disease--prediction and treatment].
    Lukás K
    Cas Lek Cesk; 2011; 150(6):315-20. PubMed ID: 21751503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
    Subramaniam K; D'Rozario J; Pavli P
    J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe complications of inflammatory bowel disease.
    Marrero F; Qadeer MA; Lashner BA
    Med Clin North Am; 2008 May; 92(3):671-86, ix. PubMed ID: 18387381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of the management of inflammatory bowel disease.
    Fell JM
    Arch Dis Child; 2012 Jan; 97(1):78-83. PubMed ID: 21505142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-art: Immunosuppression and biologic therapy.
    Sandborn WJ
    Dig Dis; 2010; 28(3):536-42. PubMed ID: 20926883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive drugs in the treatment of inflammatory bowel disease.
    Aranda R; Horgan K
    Semin Gastrointest Dis; 1998 Jan; 9(1):2-9. PubMed ID: 9547850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety issues with biological therapies for inflammatory bowel disease.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.